

SENT BY: INCYTE GENOMICS;

479 587 1075;

JUN-13-02 16:22;

PAGE 7/8

JUN. 13. 2002 2:02PM

NO. 3945 P. 1

Docket No.: PB-0009-1 CIP

REMARKS

Applicants have canceled claims 16-20 without prejudice to renewal and reserve the right to prosecute non-elected claims in subsequent divisional applications. Applicants have amended claims 1, 2, 11, and 12 to clarify the invention. Amended claim 11 is supported in the specification, for example, page 4, lines 29 through 31. Amended claim 12 is supported in the specification on page 4, lines 15 through 18. No new matter has been added by these amendments to the claims.

CONCLUSION

Applicants believe that no fee is due with this communication. However, if the USPTO determines that a fee is due, the Commissioner is hereby authorized to charge Deposit Account No. 09-0108.

Respectfully submitted,
INCYTE GENOMICS, INC.

Date: June 13, 2002

Yu-Mei Eureka Wang
Yu-Mei Eureka Wang
Reg. No. 50,510
Direct Dial Telephone: (650) 621-8740

Date: 13 June 2002

Lynn E. Murry
Lynn E. Murry
Reg. No. 49,812

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886

96014

4

09/880,192

Docket No.: PB-0009-1 CIP

"VERSION WITH MARKINGS TO SHOW CHANGES MADE"**IN THE CLAIMS**

Claims 1, 2, 11, and 12 have been amended as follows:

1. (Once Amended) A composition comprising a plurality of polynucleotides [having] wherein the polynucleotides have the nucleic acid sequences of SEQ ID NOs:1-48 or the complements of SEQ ID NOs:1-48[thereof].
2. (Once Amended) An isolated polynucleotide comprising a nucleic acid sequence of SEQ ID NO:41 and the complement of SEQ ID NO:41 [selected from SEQ ID NOs:1-48 and the complements thereof].
11. (Once Amended) The method of claim 9 wherein the sample is selected from blood or cells or tissues of the heart or vasculature [pancreatic tissue].
12. (Once Amended) The method of claim 9 wherein gene expression is compared to standards and indicates the presence of [type I diabetes] atherosclerosis, arteriosclerosis, atrial fibrillation, cancer (myxoma), complications of cancer, cardiac injury, congestive heart failure, coronary artery disease, hypertension, hypertrophic cardiomyopathy, myocardial hypertrophy, myocardial infarction, or plaque.